Fondazione Telethon Ets
BiotechFondazione Telethon Ets is a biotechnology company with 1 FDA-approved products.
Fondazione Telethon Ets's Key Drugs
Fondazione Telethon Ets's core commercial portfolio centers on waskyra — its most strategically important drugs approved in the last 15 years.
Fondazione Telethon Ets's Recent FDA Approvals
Fondazione Telethon Ets secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
Fondazione Telethon Ets's Therapeutic Areas
Disease areas where Fondazione Telethon Ets has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Fondazione Telethon Ets Pipeline Snapshot
Active clinical trials for Fondazione Telethon Ets across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • waskyra leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/1 completed
- • Speed: 85 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2025-12-08
- Latest
- 2025-12-08
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges